1.Influence of P53 on the radiotherapy response of hepatocellular carcinoma.
Ana R GOMES ; Ana M ABRANTES ; Ana F BRITO ; Mafalda LARANJO ; Joao E CASALTA-LOPES ; Ana C GONCALVES ; Ana B SARMENTO-RIBEIRO ; Maria F BOTELHO ; Jose G TRALHAO
Clinical and Molecular Hepatology 2015;21(3):257-267
BACKGROUND/AIMS: Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide, and it has a poor prognosis and few therapeutic options. Radiotherapy is one of the most effective forms of cancer treatment, and P53 protein is one of the key molecules determining how a cell responds to radiotherapy. The aim of this study was to determine the therapeutic efficacy of iodine-131 in three human HCC cell lines. METHODS: Western blotting was used to measure P53 expression. The effects of radiotherapy with iodine-131 were assessed by using the clonogenic assay to evaluate cell survival. Flow cytometry was carried out to examine the effects of iodine-131 on cell death, oxidative stress, reduced intracellular glutathione expression, the mitochondrial membrane potential, and the cell cycle. RESULTS: The P53 protein was not expressed in Hep3B2.1-7 cells, was expressed at normal levels in HepG2 cells, and was overexpressed in HuH7 cells. P53 expression in the HuH7 and HepG2 cell lines increased after internal and external irradiation with iodine-131. Irradiation induced a decrease in cell survival and led to a decrease in cell viability in all of the cell lines studied, accompanied by cell death via late apoptosis/necrosis and necrosis. Irradiation with 131-iodine induced mostly cell-cycle arrest in the G0/G1 phase. CONCLUSIONS: These results suggest that P53 plays a key role in the radiotherapy response of HCC.
Apoptosis/*radiation effects
;
Blotting, Western
;
Carcinoma, Hepatocellular/metabolism/pathology/radiotherapy
;
Cell Line, Tumor
;
Cell Survival/drug effects
;
G1 Phase Cell Cycle Checkpoints/radiation effects
;
*Gamma Rays
;
Glutathione/metabolism
;
Hep G2 Cells
;
Humans
;
Iodine Radioisotopes/chemistry/pharmacology/therapeutic use
;
Liver Neoplasms/metabolism/pathology/radiotherapy
;
Phosphorylation
;
Reactive Oxygen Species/metabolism
;
Tumor Suppressor Protein p53/*metabolism
2.Inhibition of human prostate cancer xenograft growth by 125I labeled triple-helix forming oligonucleotide directed against androgen receptor.
Yong ZHANG ; Yi MA ; Han-ping LU ; Jin-hui GAO ; Chang-sheng LIANG ; Chang-zheng LIU ; Jun-tao ZOU ; Hua-qiao WANG
Chinese Medical Journal 2008;121(22):2284-2289
BACKGROUNDThe failure of hormone treatment for advanced prostate cancer might be related to aberrant activation of the androgen receptor. We have shown that (125)I labeled triple-helix forming oligonucleotide (TFO) against the androgen receptor gene inhibits androgen receptor expression and cell proliferation of LNCaP prostate cancer cells in vitro. This study aimed at exploring the effects of the (125)I-TFO on prostate tumor growth in vivo using a nude mouse xenograft model.
METHODSTFO was labeled with (125)I by the iodogen method. Thirty-two nude mice bearing LNCaP xenograft tumors were randomized into 4 groups and were intratumorally injected with (125)I-TFO, unlabeled TFO, Na(125)I and normal saline. Tumor size was measured weekly. The tumor growth inhibition rate (RI) was calculated by measurement of tumor weight. The expression of the androgen receptor gene was performed by RT-PCR and immunohistochemical study. The prostate specific antigen (PSA) serum levels were measured by enzyme linked immunosorbent assay. The tumor cell apoptosis index (AI) was detected by TUNEL assay.
RESULTSTumor measurements showed that tumor development was significantly inhibited by either (125)I-TFO or TFO, with tumor RIs of 50.79% and 32.80% respectively. (125)I-TFO caused greater inhibition of androgen receptor expression and higher AIs in tumor tissue than TFO. Both the tumor weight and the PSA serum levels in (125)I-TFO treated mice ((0.93 +/- 0.15) g and (17.43 +/- 1.85) ng/ml, respectively) were significantly lower than those ((1.27 +/- 0.21) g and (28.25 +/- 3.41) ng/ml, respectively) in TFO treated mice (all P < 0.05). Na(125)I did not significantly affect tumor growth and androgen receptor expression in tumor tissue.
CONCLUSIONSThe (125)I-TFO can effectively inhibit androgen receptor expression and tumor growth of human prostate cancer xenografts in vivo. The inhibitory efficacy of (125)I-TFO is more potent than that of TFO, providing a reference for future studies of antigen radiotherapy.
Androgen Receptor Antagonists ; Animals ; Cell Line, Tumor ; Cell Proliferation ; drug effects ; Enzyme-Linked Immunosorbent Assay ; Humans ; Immunohistochemistry ; Iodine Radioisotopes ; Male ; Mice ; Mice, Inbred BALB C ; Mice, Nude ; Oligonucleotides ; chemistry ; pharmacology ; therapeutic use ; Prostate-Specific Antigen ; blood ; Prostatic Neoplasms ; drug therapy ; metabolism ; pathology ; Receptors, Androgen ; genetics ; metabolism ; Reverse Transcriptase Polymerase Chain Reaction ; Tumor Burden ; drug effects ; Xenograft Model Antitumor Assays ; methods